This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 584

Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

06:05AM 02/06/15

Gilead, Drug Pricing Weigh Down Biotech, But Don't Get Scared Off

By Adam Feuerstein

With shares of Gilead Sciences falling in Wednesday trading after reporting better-than-expected earnings, TheStreet senior columnist Adam Feuerstein breaks down what has investors spooked.

01:38PM 02/04/15

U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You

By Adam Feuerstein

A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.

12:59PM 02/04/15

Gilead's 2014 Earnings Were Phenomenal, but the Stock Is Falling; Here's Why

By Adam Feuerstein

The debate raging among investors is more about Gilead's future when hepatitis C revenue declines because of few available patients, greater-than-expected discounting and more competition.

07:39AM 02/04/15

Isis Pharma Time Shifts Diabetes Drug Trial to Embellish Results

By Adam Feuerstein

An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.

07:59AM 02/03/15

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report

By Adam Feuerstein

Gilead Sciences reports fourth-quarter and 2014 earnings on Tuesday after the market close.

12:22PM 02/02/15

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

By Adam Feuerstein

The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.

08:39AM 01/30/15

Dendreon's Asset Rummage Sale Completes the Circle of Life

By Adam Feuerstein

Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.

06:01AM 01/30/15

The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M

By Adam Feuerstein

If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.

07:44AM 01/29/15

Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?

By Adam Feuerstein

New trial data from a group of hepatitis C patients treated with a higher dose of RG-101 are expected in early February, according to Regulus

02:28PM 01/28/15

Page 2 of 584

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs